MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 406728 | Name: LIMKI-3
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

LIMKI-3, also known as BMS-5, is a Potent LIM kinase inhibitor (IC50 values are 7 and 8 nM for LIMK1 and LIMK2 respectively). Inhibits cofilin phosphorylation in MDA-MB-231 breast cancer cells. Reduces MDA-MB-231 tumor cell invasion in a 3D matrigel invasion assay.

Chemical Structure

LIMKI-3
LIMKI-3
CAS#1338247-35-0

Theoretical Analysis

MedKoo Cat#: 406728

Name: LIMKI-3

CAS#: 1338247-35-0

Chemical Formula: C17H14Cl2F2N4OS

Exact Mass: 430.0233

Molecular Weight: 431.28

Elemental Analysis: C, 47.34; H, 3.27; Cl, 16.44; F, 8.81; N, 12.99; O, 3.71; S, 7.43

Price and Availability

Size Price Availability Quantity
25mg USD 250.00 2 Weeks
50mg USD 450.00 2 Weeks
100mg USD 850.00 2 Weeks
200mg USD 1,250.00 2 Weeks
500mg USD 1,950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
LIMKI-3; LIMKI 3; LIMKI3; BMS-5; BMS 5; BMS5.
IUPAC/Chemical Name
N-[5-[1-(2,6-Dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl]-2-thiazolyl]-2-methylpropanamide
InChi Key
IVUGBSGLHRJSSP-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H14Cl2F2N4OS/c1-8(2)16(26)23-17-22-7-13(27-17)12-6-11(15(20)21)24-25(12)14-9(18)4-3-5-10(14)19/h3-8,15H,1-2H3,(H,22,23,26)
SMILES Code
CC(C)C(NC1=NC=C(C2=CC(C(F)F)=NN2C3=C(Cl)C=CC=C3Cl)S1)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
BMS-5 (LIMKi 3) is a potent LIMK inhibitor with IC50s of 7 nM and 8 nM for LIMK1 and LIMK2, respectively.
In vitro activity:
This study shows that pharmacological inhibition of LIMK with BMS-5 decreased the viability of Nf2(ΔEx2) MSCs in a dose-dependent manner, but did not affect viability of control MSCs. Reference: Oncogene. 2014 Jul 3;33(27):3571-82. https://pubmed.ncbi.nlm.nih.gov/23934191/
In vivo activity:
Here, using a potent LIMK inhibitor (BMS-5), this study investigated the role of LIMK activity in the dorsal hippocampus during contextual fear memory in rats. This study first found that post-training administration of BMS-5 impaired memory consolidation in a dose-dependent manner. Inhibiting LIMK before training also disrupted memory acquisition. Reference: Mol Neurobiol. 2018 Feb;55(2):958-967. https://pubmed.ncbi.nlm.nih.gov/28084590/
Solvent mg/mL mM comments
Solubility
DMSO:PBS (pH 7.2) (1:5) 0.2 0.46
Ethanol 3.0 6.96
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 431.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Petrilli A, Copik A, Posadas M, Chang LS, Welling DB, Giovannini M, Fernández-Valle C. LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2. Oncogene. 2014 Jul 3;33(27):3571-82. doi: 10.1038/onc.2013.320. Epub 2013 Aug 12. PMID: 23934191; PMCID: PMC4016185. 2. Scott RW, Hooper S, Crighton D, Li A, König I, Munro J, Trivier E, Wickman G, Morin P, Croft DR, Dawson J, Machesky L, Anderson KI, Sahai EA, Olson MF. LIM kinases are required for invasive path generation by tumor and tumor-associated stromal cells. J Cell Biol. 2010 Oct 4;191(1):169-85. doi: 10.1083/jcb.201002041. Epub 2010 Sep 27. PMID: 20876278; PMCID: PMC2953444. 3. Lunardi P, Sachser RM, Sierra RO, Pedraza LK, Medina C, de la Fuente V, Romano A, Quillfeldt JA, de Oliveira Alvares L. Effects of Hippocampal LIMK Inhibition on Memory Acquisition, Consolidation, Retrieval, Reconsolidation, and Extinction. Mol Neurobiol. 2018 Feb;55(2):958-967. doi: 10.1007/s12035-016-0361-x. Epub 2017 Jan 13. PMID: 28084590.
In vitro protocol:
1. Petrilli A, Copik A, Posadas M, Chang LS, Welling DB, Giovannini M, Fernández-Valle C. LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2. Oncogene. 2014 Jul 3;33(27):3571-82. doi: 10.1038/onc.2013.320. Epub 2013 Aug 12. PMID: 23934191; PMCID: PMC4016185. 2. Scott RW, Hooper S, Crighton D, Li A, König I, Munro J, Trivier E, Wickman G, Morin P, Croft DR, Dawson J, Machesky L, Anderson KI, Sahai EA, Olson MF. LIM kinases are required for invasive path generation by tumor and tumor-associated stromal cells. J Cell Biol. 2010 Oct 4;191(1):169-85. doi: 10.1083/jcb.201002041. Epub 2010 Sep 27. PMID: 20876278; PMCID: PMC2953444.
In vivo protocol:
1. Lunardi P, Sachser RM, Sierra RO, Pedraza LK, Medina C, de la Fuente V, Romano A, Quillfeldt JA, de Oliveira Alvares L. Effects of Hippocampal LIMK Inhibition on Memory Acquisition, Consolidation, Retrieval, Reconsolidation, and Extinction. Mol Neurobiol. 2018 Feb;55(2):958-967. doi: 10.1007/s12035-016-0361-x. Epub 2017 Jan 13. PMID: 28084590.
1: Wang W, Townes-Anderson E. LIM Kinase, a Newly Identified Regulator of Presynaptic Remodeling by Rod Photoreceptors After Injury. Invest Ophthalmol Vis Sci. 2015 Dec;56(13):7847-58. doi: 10.1167/iovs.15-17278. PubMed PMID: 26658506; PubMed Central PMCID: PMC4682489. 2: Bao Z, Han X, Chen F, Jia X, Zhao J, Zhang C, Yong C, Tian S, Zhou X, Han L. Evidence for the involvement of cofilin in Aspergillus fumigatus internalization into type II alveolar epithelial cells. BMC Microbiol. 2015 Aug 13;15:161. doi: 10.1186/s12866-015-0500-y. PubMed PMID: 26268695; PubMed Central PMCID: PMC4542120. 3: Park JB, Agnihotri S, Golbourn B, Bertrand KC, Luck A, Sabha N, Smith CA, Byron S, Zadeh G, Croul S, Berens M, Rutka JT. Transcriptional profiling of GBM invasion genes identifies effective inhibitors of the LIM kinase-Cofilin pathway. Oncotarget. 2014 Oct 15;5(19):9382-95. PubMed PMID: 25237832; PubMed Central PMCID: PMC4253441. 4: Petrilli A, Copik A, Posadas M, Chang LS, Welling DB, Giovannini M, Fernández-Valle C. LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2. Oncogene. 2014 Jul 3;33(27):3571-82. doi: 10.1038/onc.2013.320. Epub 2013 Aug 12. PubMed PMID: 23934191; PubMed Central PMCID: PMC4016185.